KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Accumulated Depreciation & AmortizationEBIATLong-Term Debt IssuancesR&D In ProcessShares RepurchasedShort-Term Debt issuances
Ratios

Eli Lilly (LLY) Long-Term Debt Repayments (2016 - 2022)

Historic Long-Term Debt Repayments for Eli Lilly (LLY) over the last 14 years, with Q2 2022 value amounting to $849.9 million.

  • Eli Lilly's Long-Term Debt Repayments changed N/A to $849.9 million in Q2 2022 from the same period last year, while for Mar 2023 it was $849.9 million, marking a year-over-year decrease of 6750.53%. This contributed to the annual value of $664.2 million for FY2024, which is N/A changed from last year.
  • Latest data reveals that Eli Lilly reported Long-Term Debt Repayments of $849.9 million as of Q2 2022.
  • Eli Lilly's 5-year Long-Term Debt Repayments high stood at $2.3 billion for Q4 2019, and its period low was $100000.0 during Q3 2019.
  • In the last 5 years, Eli Lilly's Long-Term Debt Repayments had a median value of $276.3 million in 2020 and averaged $586.0 million.
  • Per our database at Business Quant, Eli Lilly's Long-Term Debt Repayments skyrocketed by 6696666.67% in 2018 and then tumbled by 9999.12% in 2020.
  • Over the past 5 years, Eli Lilly's Long-Term Debt Repayments (Quarter) stood at $7.6 million in 2018, then skyrocketed by 29717.11% to $2.3 billion in 2019, then crashed by 99.99% to $200000.0 in 2020, then plummeted by 50.0% to $100000.0 in 2021, then skyrocketed by 849800.0% to $849.9 million in 2022.
  • Its Long-Term Debt Repayments stands at $849.9 million for Q2 2022, versus $710.1 million for Q1 2022 and $100000.0 for Q4 2021.